
Sign up to save your podcasts
Or


Liz Christo is a Partner at Stage 2 Capital, the fund headed by Mark Roberge, the founding CRO at HubSpot.
Before Stage 2, Liz spent 6 years at OpenView leading the Expansion Platform working with the likes of Calendly, Expensify & DataDog.
Prior to that, Liz spent a decade as an operator and was the AVP of BD at NetSuite, launching and scaling NetSuite’s BDR team to a 170-person global organisation.
This is a sales focused episode where we explore everything from defining a playbook, tweaking for PLG when doing sales led growth, compensation planning, how to best prospect and so much more. It’s a must listen for any early stage founder to build out an early sales team.
Will Bennett and Sivesh Sukumar are investors at Seedcamp and Balderton Capital, two premier European VC firms.
Balderton has been investing in Europe for more than 20 years having one of the best portfolios in the continent including companies like Revolut, Dream Games, Contentful and Aircall, spurred by two funds, early and growth, and the ability to write checks up to $60m.
Seedcamp is now on its 6th fund of $180m, writing up to $1m cheques across sectors. It’s third fund is recognised as one of the best performing globally, with six unicorns in its portfolio, also including Revolut, wefox and UiPath.
Brought to you by TAV, Will and Sivesh join Jack and Rich to discuss everything AI; how emerging startups can get an edge on incumbents, distribution, domination of models, regulation, whether we’re in a hype cycle or not and so much more.
Harrison Rose is an extraordinary entrepreneur having founded Paddle, the unicorn payments infrastructure provider for SaaS companies that has raised over $300m from Notion, KKR, FTV Capital, Kindred and 83North.
Harrison left Paddle in 2022 to pursue his next venture, Goodfit, a platform that maximises sales & marketing efficiency with commercial data.
Brought to you by TAV, Harrison joins Jack and Rich to discuss his journey as an 18 year old founder straight out of school, honing ICPs, wearing many different hats as a founder, the decision to leave Paddle and so much more.
James Peyer is the CEO and founder of Cambrian Bio, a company that develops therapeutics targeting key biological pathways that decline or malfunction with age to create medicines that have the potential to treat and prevent some of today's most debilitating diseases.
Cambrian is viewed as one of the most exciting biotech companies around, raising $160m in the last 5 years.
Brought to you by TAV, James joins Jack and Rich to discuss his personal journey, longevity, Cambrian's journey to human trials, regulatory considerations and so much more.
From the publisher's feed